296 related articles for article (PubMed ID: 33641042)
21. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
[TBL] [Abstract][Full Text] [Related]
22. Malignant peripheral nerve sheath tumors of the spine: results of surgical management from a multicenter study.
Chou D; Bilsky MH; Luzzati A; Fisher CG; Gokaslan ZL; Rhines LD; Dekutoski MB; Fehlings MG; Ghag R; Varga P; Boriani S; Germscheid NM; Reynolds JJ;
J Neurosurg Spine; 2017 Mar; 26(3):291-298. PubMed ID: 27834629
[TBL] [Abstract][Full Text] [Related]
23. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
Ahsan S; Ge Y; Tainsky MA
Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
[TBL] [Abstract][Full Text] [Related]
24. Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Widemann BC
Curr Oncol Rep; 2009 Jul; 11(4):322-8. PubMed ID: 19508838
[TBL] [Abstract][Full Text] [Related]
25. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
[TBL] [Abstract][Full Text] [Related]
26. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
27. Malignant peripheral nerve sheath tumors: Analysis of the national cancer database.
Mowery A; Clayburgh D
Oral Oncol; 2019 Nov; 98():13-19. PubMed ID: 31525622
[TBL] [Abstract][Full Text] [Related]
28. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
[TBL] [Abstract][Full Text] [Related]
29. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
30. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
Friedrich RE; Kluwe L; Fünsterer C; Mautner VF
Anticancer Res; 2005; 25(3A):1699-702. PubMed ID: 16033085
[TBL] [Abstract][Full Text] [Related]
31. Analysis of treatment sequence and outcomes in patients with relapsed malignant peripheral nerve sheath tumors.
Zhang L; Lemberg KM; Calizo A; Varadhan R; Siegel AH; Meyer CF; Blakeley JO; Pratilas CA
Neurooncol Adv; 2023; 5(1):vdad156. PubMed ID: 38130899
[TBL] [Abstract][Full Text] [Related]
32. Management of childhood malignant peripheral nerve sheath tumor.
Ferrari A; Bisogno G; Carli M
Paediatr Drugs; 2007; 9(4):239-48. PubMed ID: 17705563
[TBL] [Abstract][Full Text] [Related]
33. TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death.
Qin W; Godec A; Zhang X; Zhu C; Shao J; Tao Y; Bu X; Hirbe AC
Cancer Med; 2019 Sep; 8(11):5232-5241. PubMed ID: 31278855
[TBL] [Abstract][Full Text] [Related]
34. Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors.
Lamm W; Schur S; Köstler WJ; Funovics P; Windhager R; Amann G; Panotopoulos J; Pokrajac B; Brodowicz T
Oncology; 2014; 86(2):122-6. PubMed ID: 24480823
[TBL] [Abstract][Full Text] [Related]
35. Malignant peripheral nerve sheath tumor of the maxilla: Case report and review of the literature with emphasis on its poor prognosis.
Oh KY; Hong SD
Oral Oncol; 2022 Dec; 135():106211. PubMed ID: 36257181
[TBL] [Abstract][Full Text] [Related]
36. Treatment of malignant peripheral nerve sheath tumors in pediatric NF1 disease.
Martin E; Flucke UE; Coert JH; van Noesel MM
Childs Nerv Syst; 2020 Oct; 36(10):2453-2462. PubMed ID: 32494969
[TBL] [Abstract][Full Text] [Related]
37. Malignant peripheral nerve sheath tumors - Outcomes and prognostic factors based on the reference center experience.
Sobczuk P; Teterycz P; Czarnecka AM; Świtaj T; Koseła-Paterczyk H; Kozak K; Falkowski S; Goryń T; Zdzienicki M; Morysiński T; Rutkowski P
Surg Oncol; 2020 Dec; 35():276-284. PubMed ID: 32949967
[TBL] [Abstract][Full Text] [Related]
38. Metastatic Malignant Peripheral Nerve Sheath Tumor With NF1 Successfully Treated With 'Gradual Subtraction' ICE Chemotherapy.
Wang Y; Katagiri H; Murata H; Wasa J; Miyagi M; Kakuda Y; Takahashi M
Anticancer Res; 2020 Mar; 40(3):1619-1624. PubMed ID: 32132065
[TBL] [Abstract][Full Text] [Related]
39. Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review.
Ziadi A; Saliba I
Auris Nasus Larynx; 2010 Oct; 37(5):539-45. PubMed ID: 20399579
[TBL] [Abstract][Full Text] [Related]
40. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1.
McCaughan JA; Holloway SM; Davidson R; Lam WW
J Med Genet; 2007 Jul; 44(7):463-6. PubMed ID: 17327286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
